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Background: Prospective cohort studies of circulating sex steroid hormones and
prostate cancer risk have not provided a consistent association, despite evidence
from animal and clinical studies. However, studies using male pattern baldness as a
proxy of early-life or cumulative androgen exposure have reported significant
associations with aggressive and fatal prostate cancer risk. Given that androgens
underlie the development of patterned hair loss and chest hair, we assessedwhether
these two dermatological characteristics were associated with circulating and
intraprostatic concentrations of sex steroid hormones among men diagnosed with
localized prostate cancer.
Methods: We included 248 prostate cancer patients from the NCI Prostate Tissue
Study, who answered surveys and provided a pre-treatment blood sample as well as
fresh frozen adjacent normal prostate tissue. Male pattern baldness and chest hair
density were assessed by trained nurses before surgery. General linear models
estimated geometricmeans and 95% confidence intervals (95%CIs) of each hormone
variable by dermatological phenotype with adjustment for potential confounding
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variables. Subgroup analyses were performed by Gleason score (<7 vs ≥7) and race
(European American vs. African American).
Results: We found strong positive associations of balding status with serum
testosterone, dihydrotestosterone (DHT), estradiol, and sex hormone-binding
globulin (SHBG), and a weak association with elevated intraprostatic testosterone.
Conversely, neither circulating nor intraprostatic sex hormones were statistically
significantly associated with chest hair density. Age-adjusted correlation between
binarybalding status and three-level chest hair densitywasweak (r = 0.05). Therewas
little evidence to suggest that Gleason score or race modified these associations.
Conclusions:This study provides evidence that balding status assessed at amean age
of 60 yearsmay serve as a clinicalmarker for circulating sex hormone concentrations.
The weak-to-null associations between balding status and intraprostatic sex
hormones reaffirm differences in organ-specific sex hormone metabolism, implying
that other sex steroid hormone-related factors (eg, androgen receptor) play
important roles in organ-specific androgenic actions, and that other overlapping
pathways may be involved in associations between the two complex conditions.
K E YWORD S
chest hair density, male pattern baldness, prostate tissue, serum, sex steroid hormones
1 | INTRODUCTION
Androgens have long been hypothesized to underlie the development
of prostate cancer. However, the association between serum sex
steroid hormones and prostate cancer risk remains inconsistent. A
meta-analysis of 18 prospective studies reported null associations
using study-specific circulating concentrations,1 albeit limited by the
use of blood at a single time-point after midlife that may have missed
the etiologically relevant time window, and a potentially diluted effect
through inclusion of a variable proportion of indolent prostate cancer
cases in the era of prostate-specific antigen (PSA) testing. Later
epidemiologic studies also did not support the association between
circulating sex steroid hormones and prostate cancer risk,2–4 although
some subgroup analyses reported a positive association of aggressive
prostate cancer with total testosterone/sex hormone-binding globulin
(SHBG) ratio,5,6 and an inverse association with the highest quintile of
total estradiol/total testosterone ratio.7
Despite the paucity of evidence for an association between
circulating sex steroid hormones and prostate cancer risk, androgenic
alopecia (also commonly known as male pattern baldness) used as a
proxy for early-life or cumulative exposure to sex steroid hormones
has been reported to be associated with aggressive and fatal prostate
cancer.8–10Male pattern baldness is the most common hair loss in men
and affects approximately 50% of Caucasianmen by age 50. Bald scalp
overexpresses androgen receptor (AR)11–14 and has higher levels of
dihydrotestosterone (DHT),15 compared with the non-bald region.
This enhanced androgenic action induces miniaturization of scalp hair
follicles and causes progressive hair loss.16 On the other hand, men
born with 5α-reductase type II (5αR2, which intracellularly converts
testosterone to DHT) deficiency,17 or castrated before puberty show
complete retention of scalp hair.18 The former observation has led to
the use of finasteride (a 5αR2 inhibitor) in balding treatment, which
slows scalp hair loss and promotes new scalp hair growth.19
Although no study has assessed the direct relationship between
chest hair density and prostate cancer risk, associations between chest
hair density and circulating sex steroid hormones have been reported.
The development of chest hair parallels the surge of androgens in men
during puberty.20 Denser chest hair has been correlated with higher
levels of circulating 3α-androstanediol glucuronide (3α-diol-G; a
metabolite of DHT in peripheral tissue)21 and lower SHBG concen-
trations.22 Given the role of androgenic action in these dermatological
phenotypes, we investigated clinically assessed balding status and
chest hair density in relation to circulating and intraprostatic
concentrations of sex steroid hormones in the NCI Prostate Tissue
Study in an attempt to understand the potential biological mechanisms
underlying associations between the dermatological phenotypes and
prostate cancer risk.
2 | MATERIALS AND METHODS
2.1 | Study population
A detailed description of the Prostate Tissue Study has been reported
elsewhere.23 In brief, 422 patients were enrolled from five hospitals
during January 2000 to April 2004. Eligible study subjects were
men aged 18 years or older, scheduled for prostatectomy or
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cystoprostatectomy, newly diagnosed with localized prostate cancer,
and had not taken any medication that may influence sex steroid
hormone concentrations (eg, dehydroepiandrosterone [DHEA], finas-
teride, and neoadjuvant hormone therapy) during the 24 h preceding
surgery.
Each patient provided 30mL of fasting blood before surgery,
which was aliquoted within 4 h at room temperature and subsequently
frozen at −70°C. During surgery and immediately after the prostate
gland was resected, the pathologist sliced a maximum of three pieces
of macroscopically normal tissue from each of the peripheral and non-
peripheral zones of the prostate, each piece weighing 200-400mg.
Each macroscopically normal tissue had the ends trimmed and fixed in
formalin for Haemotoxylin and Eosin stain. A genitourinary pathologist
(I.A.S.) subsequently evaluated the morphology and histology of these
margins to rule out slices containing cancer. The remaining tissue was
placed in a pre-labeled cryovial, flash frozen in liquid nitrogen and
stored at −70°C.
Each patient underwent a physical examination before surgery by
trained hospital nurses for anthropometric and dermatological
information and a follow-up telephone interview approximately six
weeks after surgery for information on demographics, medical history,
family history of cancer, and lifestyle. Medical and pathology reports
were also extracted.
2.2 | Sex steroid hormone quantitation
Sex steroid hormones were quantified at the University of Southern
California under the direction of F.Z.S. A detailed description of sample
handling and laboratory process have been previously reported.23 In
brief, serum concentrations of total testosterone (testosterone), DHT,
4-Androstene-3, 17-dione (androstenedione), estrone, and total
estradiol (estradiol) were measured by in-house radioimmunoassays
(RIA), 3α-diol-G was measured by a commercial RIA kit (Diagnostics
Systems Laboratories, Webster TX, presently Beckman-Coulter,
Minneapolis, MD), and SHBG was measured by a solid-phase, two-
site chemiluminescent immunometric assay on the Immulite analyzer
(Diagnostic Products Corporation, Los Angeles, CA, presently Siemens
Healthcare Diagnostics, Deerfield, IL) during 2007. RIAs were used
after organic solvent extraction to remove conjugated steroids and
Celite column partition chromatography to separate potential
interfering unconjugated steroids. In addition, highly specific antisera
were used in the RIAs to provide added specificity. Concentrations of
serum free testosterone and free estradiol were calculated using
validated algorithms.24,25 Coefficients of variation (CV)—calculated on
the logarithmic scale using a mixed model which included 2-7
replicates from each of seven different individuals—were all less
than 15% (mean = 10%).
Intraprostatic sex steroid hormones, including androstenedione,
testosterone, DHT, 3α-diol-G, estrone, and estradiol, were extracted
from each homogenized prostate tissue sample weighing 100-
400mg during 2008-2009. These hormones then underwent the
same preparation procedures and RIAs as in the serum hormone
quantitation, and were expressed as picograms per gram of wet
tissue weight. In-house assays for tissue hormones had small
technical variability with CVs below 20% (mean = 13.8%) for all,
except for androstenedione (21%). CVs were calculated on the
logarithmic scale using a mixed model including an average of six
technical replicates from each of five different individuals. For
intraprostatic sex steroid hormone analysis, we used all eligible
pieces of adjacent normal tissue regardless of sampling locations to
calculate subject-level mean concentrations, as our pilot study of 30
prostate cancer patients showed that this provided generally
superior CV and intra-class correlation coefficient (ICC) values,
compared with using the mean concentrations of solely peripheral or
solely non-peripheral tissue.23 Both serum and tissue sex steroids
RIAs used tritiated internal standards, and the concentrations were
corrected for procedural losses ranging from 15% to 30%.
2.3 | Exposure measurement
Trained hospital nurses assessed scalp hair pattern using a Norwood-
Hamilton Scale26 and grouped participants into three categories: 1)
no/little baldness (I/II); 2) vertex baldness (III-vertex, IV/V/Va/VI,
and VII); and 3) frontal baldness (IIa/III/IIIa/IVa) (Supplementary
Figure S1). A previous validation study asked dermatologists and
residents to rate balding patterns using Norwood-Hamilton scale
against photographs of male heads, reporting modest ICCs (0.63-
0.68) for original classes and recommending reduced classes to
achieve higher ICCs.27 Therefore, the three-level balding variable
was further collapsed into two categories: no/little versus any
baldness to minimize potential misclassification. Chest hair density
was originally measured on the Ferriman-Gallwey five-level scale (ie,
none, sparse, moderate, dense, and very dense).28 A previous
validation study reported good inter-observer agreement
(kappa = 0.80) for the original scale among Turkish women.29 This
variable was subsequently collapsed into three categories in the
analysis: none-to-sparse (lowest two levels), moderate, and dense
(highest two levels).
2.4 | Analytic sample
Of 422 enrolled patients, we included 248 prostate cancer patients
for this analysis, after excluding 148 without sex hormones assayed
in tissue, 14 without a diagnosis of prostate cancer, one without
serum hormones and 11 without any measured dermatological
information.
2.5 | Statistical analysis
Pearson χ2 tests assessed independence of categorical patient
characteristics from balding status and chest hair density. Partial
Spearmen's correlation coefficients were estimated for pairs of
circulating and intraprostatic sex hormones, adjusting for continuous
age at surgery and body mass index (BMI, kg/m2). General linear
models estimated geometric means and 95% confidence intervals
(95%CIs) of hormones by balding status, chest hair density andGleason
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score (from prostatectomy or biopsy) with adjustment for pre-defined
potential confounding variables including age at surgery, study site,
race, BMI, education, smoking status, and regular alcohol use. As
hormone variables were skewed, natural log transformation was
applied to non-missing values, and patients with missing values were
dropped from regression models for individual hormone variables.
Missing values of potential confounding variables were included in
regression models as a separate category. Subgroup analyses were
performedbyGleason score (<7 vs≥7) and race (EuropeanAmerican vs
African American).
We also conducted two sensitivity analyses: 1) for intraprostatic
sex steroid hormones, we used the mean concentrations of two
randomly selected tissue pieces to evaluate the robustness of themain
results in general linear models, given the potential variation in
measurement errors from the use of a variable number of eligible tissue
pieces per subject (median = 4); and 2) we alternatively modeled
balding status or three-level chest hair density as the outcome and
tertiles of each hormone variable as the exposure using binary and
ordinal logistic regression, respectively. To assess trends across
tertiles, we assigned the median value of each tertile and modeled
this as a continuous variable in logistic regressions.
Two-sided P values <0.05were considered statistically significant.
SAS v9.3 (SAS Institute, Inc., Cary, NC)was used for statistical analyses.
3 | RESULTS
Of the 248 patients in this analysis, 144 (58%) presented some degree of
baldness and 52 (22%) some degree of dense chest hair (Table 1). Age-
adjusted correlation between binary balding status and three-level chest
hair density wasweak (r = 0.05). Patient characteristics distributed evenly
by balding status, while patientswith dense chest hair weremore likely to
be European Americans, have a college degree or higher, and have high-
grade prostate cancer. After adjustment for age, differences in these
characteristics by chest hair density becameminimal (data not tabulated).
Supplemental Table S1 shows the distribution of crude concentrations of
sex hormones and SHBG. Partial Spearmen's correlation coefficients
adjusted for age and BMI demonstrated very strong correlations for pairs
of testosterone and DHT (r = 0.74), testosterone and SHBG (r = 0.68),
testosterone and estradiol (r = 0.53), DHT and SHBG (r = 0.61), and
estrone and estradiol (r = 0.66) in serum, as well as estrone and estradiol
(r = 0.64) in tissue (data not tabulated).
Geometric means of hormone variables by balding status are
shown in Table 2. Bald patients were more likely to have higher
serum testosterone, DHT, estrone, estradiol, and SHBG, as well as
higher intraprostatic testosterone concentrations with full adjust-
ment for potential confounding variables. Stratified analyses by
Gleason score showed that such associations were mainly observed
in Gleason score ≥7 prostate cancers, although the multiplicative
interaction between balding status and Gleason score for each
hormone variable was not statistically significant (Supplemental
Table S2). Meanwhile, stratified analyses by race demonstrated that
only bald European Americans had statistically significantly higher
testosterone, DHT, and SHBG in serum, and estrone, estradiol, and
androstenedione/estrone ratio in tissue (Supplemental Table S3).
However, associations were in the same direction among African
Americans, and multiplicative interactions were null between balding
status and race for individual hormone variables. Given androgenic
sensitivity differs by scalp region,15 we also presented geometric
means by three-level scalp balding category in Supplemental
Table S4, despite limited counts for frontal balding only (n = 20).
Distributions of hormone variables were similar between frontal
balding only and vertex plus frontal balding, although the latter
group appeared to have higher androstenedione in serum
(P = 0.013).
Sensitivity analyses in which tertiles of each hormone variable
were modeled as the exposure, as opposed to the outcome, provided
mostly consistent results, except that the association for intraprostatic
testosterone concentrations became null and an inverse association
for intraprostatic androstenedione/estrone ratio was observed
(adjusted Ptrend = 0.042, Supplemental Table S5). Increased SHBG
appeared to drive the association for testosterone in serum; when we
modeled testosterone and SHBG simultaneously, the positive
association for testosterone was attenuated to the null (ORthird tertile
vs first tertile = 1.62, 95%CI = 0.67-3.91), whereas the positive associa-
tion for SHBG remained significant (ORthird tertile vs first tertile = 3.00, 95%
CI = 1.19-7.53) (data not tabulated). Results were consistent when we
simultaneously modeled testosterone and SHBG as continuous
variables (Ptestosterone = 0.83 and PSHBG = 0.01). Tentative evidence
was found that increased testosterone drove the association for
estradiol in serum, as simultaneous adjustment for continuous
testosterone and estradiol attenuated the association for estradiol
to the null (Pestradiol = 0.197 and Ptestosterone = 0.05), but simultaneous
adjustment for tertiles of these hormones attenuated the associations
to the null for both estradiol (ORthird tertile vs first tertile = 2.16, 95%
CI = 0.90-5.20) and testosterone (ORthird tertile vs first tertile = 2.03, 95%
CI = 0.90-4.57) (data not tabulated).
Geometric means of hormone variables by chest hair density
provided no evidence of an association (Table 3). There was little
evidence for effect modification by Gleason score (Supplemental
Table S6) or race (Supplemental Table S7). Compared with the main
results for chest hair density, modeling tertiles of each hormone
variables as the exposure resulted in similarly null associations
(Supplemental Table S5).
Sensitivity analyses for intraprostatic sex steroid hormones that
used two pieces of randomly selected adjacent normal tissue per
subject did not materially alter the results, compared with the main
models that used all eligible tissues (data not tabulated).
4 | DISCUSSION
In this study, serum and intraprostatic sex steroid hormones were
quantified in relation tomale pattern baldness and chest hair density in
men diagnosed with localized prostate cancer. We found evidence for
strong positive associations of circulating testosterone, DHT, estradiol,
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and SHBG with male pattern baldness. However, we found limited
evidence for associations between intraprostatic sex hormones and
baldness, although the direction of these associations was consistent
with what was observed in the serum analyses. Neither circulating nor
intraprostatic sex hormones were statistically significantly associated
with chest hair density. There was little evidence to suggest that
Gleason score or race modified these relationships, although the
statistical power for interaction tests may be limited by the modest
sample size.
Both the prostate gland and human hair follicles are responsive to
sex steroid hormones. Testosterone produced by Leydig cells of the
testes is the predominant circulating androgen in men and is
TABLE 1 Patient characteristics by balding status and chest hair density (N = 248)
Balding status (n = 248) Chest hair density (n = 239)a
Characteristics No (n = 104) Any (n = 144) P-valueb None/sparse (n = 110) Moderate (n = 77) Dense (n = 52) P-valueb
Age at surgery (years)
N 104 143 109 77 52
Mean (SD) 58.4 (8.1) 60.4 (6.4) 0.055c 60.0 (7.3) 59.4 (7.6) 59.0 (6.4) 0.803c
≤55 37 (35.6%) 32 (22.2%) 0.088d 27 (24.5%) 23 (29.9%) 16 (30.8%) 0.945d
56-60 23 (22.1%) 44 (30.6%) 32 (29.1%) 20 (26.0%) 14 (26.9%)
61-65 25 (24.0%) 32 (22.2%) 26 (23.6%) 16 (20.8%) 13 (25.0%)
>65 19 (18.3%) 35 (24.3%) 24 (21.8%) 18 (23.4%) 9 (17.3%)
Race 0.291 <0.001
European American 61 (58.7%) 73 (50.7%) 40 (36.4%) 50 (64.9%) 36 (69.2%)
African American 38 (36.5%) 68 (47.2%) 66 (60.0%) 26 (33.8%) 13 (25.0%)
Other 3 (2.9%) 3 (2.1%) 4 (3.6%) 1 (1.3%) 1 (1.9%)
Education 0.935 <0.001
Less than high school 8 (7.7%) 12 (8.3%) 16 (14.5%) 3 (3.9%) 0 (0%)
High school/Technical school 25 (24.0%) 33 (22.9%) 26 (23.6%) 23 (29.9%) 9 (17.3%)
College or higher 58 (55.8%) 73 (50.7%) 50 (45.5%) 35 (45.5%) 38 (73.1%)
Gleason score 0.822 0.009
<7 56 (53.8%) 81 (56.3%) 57 (51.8%) 53 (68.8%) 20 (38.5%)
=7 38 (36.5%) 55 (38.2%) 42 (38.2%) 23 (29.9%) 28 (53.8%)
>7 6 (5.8%) 6 (4.2%) 6 (5.5%) 1 (1.3%) 4 (7.7%)
Body mass index (BMI, kg/m2)
N 102 143 109 77 51
Mean (SD) 26.9 (3.3) 28.1 (10.4) 0.358c 26.7 (3.9) 29.1 (13.7) 27.3 (2.9) 0.139c
<25.0 29 (27.9%) 37 (25.7%) 0.593d 36 (32.7%) 18 (23.4%) 11 (21.2%) 0.115d
25.0-29.9 58 (55.8%) 76 (52.8%) 57 (51.8%) 38 (49.4%) 33 (63.5%)
≥30.0 17 (16.3%) 31 (21.5%) 17 (15.5%) 21 (27.3%) 8 (15.4%)
Smoking status 0.295 0.162
Never 38 (36.5%) 48 (33.3%) 36 (32.7%) 25 (32.5%) 23 (44.2%)
Former 38 (36.5%) 55 (38.2%) 39 (35.5%) 32 (41.6%) 16 (30.8%)
Current 12 (11.5%) 8 (5.6%) 12 (10.9%) 2 (2.6%) 5 (9.6%)
Regular alcohol use 0.087 0.347
Never 31 (29.8%) 45 (31.3%) 35 (31.8%) 23 (29.9%) 14 (26.9%)
Former 11 (10.6%) 25 (17.4%) 19 (17.3%) 9 (11.7%) 5 (9.6%)
Current 49 (47.1%) 47 (32.6%) 38 (34.5%) 29 (37.7%) 27 (51.9%)
Column percentage does not add up to 100% due to missing data.
aNine prostate cancer patients were excluded for tabulation of chest hair density due to missing data.
bP-values were computed byWilcoxon Rank-sum test for continuous variables and Chi-square/Fisher's exact test for categorical variables using non-missing
values.
cP-values were calculated for the continuous covariate.
dP-values were calculated for the categorical covariate.
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irreversibly converted to the most potent androgen, DHT, by 5αR in
many peripheral tissues, such as the prostate and skin. DHT and, to a
lesser extent, testosterone intracellularly bind to AR stimulating
downstream androgenic action including hair stimulation and inhibi-
tion, as well as prostate growth and carcinogenesis. There are three
isoenzymes of 5αR (types I, II, and III). The function of 5αR3 in the
prostate remains unclear but previous studies reported its role in
converting testosterone to DHT in castration resistant prostate
cancers.30,31 Meanwhile, 5αR1 and 5αR2 are consistently related to
testosteronemetabolism, and are expressed at different body sites and
organ compartments.32 Prostatic epithelium and stroma express
higher concentrations of 5αR2,33 as highlighted by an efficient
reduction in intraprostatic DHT through finasteride treatment27 and
by its comparable efficacy to dutasteride (a dual inhibitor for 5αR1 and
5αR2) treatment for benign prostatic hyperplasia.34 Meanwhile,
sebaceous glands predominantly express 5αR1, and scalp hair follicles
produce higher levels of 5αR2.35–37 Both isoenzymes play critical roles
in balding development as supported by the superior efficacy of
dutasteride versus finasteride in treating baldness.38,39 Lastly, 5αR1 is
the predominant form expressed in chest skin.40 However, chest hair
follicles have been suggested to be less androgen-dependent,41 and
this is in line with the null association of chest hair density with sex
steroid hormones in this analysis, albeit two prior observational studies
have reported otherwise.21,22
Direct comparison of results from epidemiological studies on
circulating sex hormones in relation to male pattern baldness is
challenging given differences in age, race, laboratory assays (eg, RIA,
mass spectrometry, electrochemiluminescence immunoassay),
health status (with/without malignancy/other metabolic diseases),
and balding categories. Several small studies (n = 6) have assessed
this relationship among apparently healthy younger (<45 years old)
men and found conflicting associations; some reported that bald
men were more likely to have increased testosterone,15,42 increased
testosterone/SHBG ratio,42,43 increased DHT15 and decreased
SHBG levels,42–44 whereas others have reported either null or
opposing findings.45,46 On the other hand, a cross-sectional study
among older (>65 years) healthy Greek men specifically compared
vertex balding to those without (ie, no/minimal plus frontal balding
TABLE 2 Geometric means of sex steroid hormones and SHBG by balding status at mean age of 60 years (N = 248)
Minimally adjusteda Fully adjustedb
Sex hormones N No (n = 104) Any (n = 144) P-valuec No (n = 104) Any (n = 144) P-valuec
Serum (ng/dl)
T 248 420.1 (387.9, 455.0) 481.5 (450.1, 515.1) 0.012 416.4 (384.1, 451.3) 484.6 (452.8, 518.6) 0.006
DHT 248 46.4 (43.0, 50.0) 53.7 (50.4, 57.2) 0.004 45.9 (42.7, 49.4) 54.1 (50.9, 57.5) 0.001
3α-diol-G 248 507.2 (458.3, 561.2) 492.3 (451.9, 536.3) 0.663 500.3 (451.4, 554.4) 497.2 (456.0, 542.1) 0.930
A 248 67.9 (62.7, 73.4) 70.1 (65.6, 75.0) 0.539 66.9 (61.7, 72.5) 70.9 (66.2, 75.9) 0.294
E1 248 5.0 (4.7, 5.4) 5.6 (5.3, 5.9) 0.030 5.0 (4.7, 5.4) 5.6 (5.3, 5.9) 0.027
E2 248 2.9 (2.7, 3.1) 3.3 (3.1, 3.5) 0.004 2.9 (2.7, 3.1) 3.2 (3.1, 3.4) 0.010
T/E2 ratio 248 147.7 (135.8, 160.6) 147.1 (137.0, 157.9) 0.948 144.9 (134.0, 156.7) 149.1 (139.6, 159.3) 0.592
A/E1 ratio 248 13.5 (12.4, 14.6) 12.6 (11.8, 13.6) 0.242 13.3 (12.3, 14.4) 12.8 (11.9, 13.7) 0.458
SHBG (nmol/L) 248 29.8 (27.7, 32.0) 35.4 (33.3, 37.6) 0.001 29.7 (27.7, 31.9) 35.4 (33.4, 37.6) <0.001
Free T 248 10.7 (9.9, 11.4) 11.4 (10.8, 12.1) 0.140 10.6 (9.8, 11.4) 11.5 (10.8, 12.2) 0.092
Free E2 248 0.08 (0.08, 0.09) 0.09 (0.08, 0.09) 0.064 0.08 (0.08, 0.09) 0.09 (0.08, 0.09) 0.138
Adjacent normal prostate tissue (pg/g W)
T 245 205.1 (187.7, 224.1) 230.5 (214.1, 248.0) 0.051 204.3 (186.8, 223.4) 230.9 (214.4, 248.6) 0.045
DHT 248 6433.6 (6080.3, 6807.4) 6663.9 (6353.2, 6989.8) 0.357 6456.1 (6104.7, 6827.7) 6647.1 (6341.3, 6967.7) 0.446
3α-diol-G 244 2599.8 (2402.7, 2813.1) 2704.4 (2527.2, 2894.1) 0.463 2568.4 (2372.7, 2780.2) 2731.1 (2552.3, 2922.5) 0.261
A 229 593.3 (537.8, 654.5) 579.4 (534.1, 628.6) 0.719 585.1 (529.9, 646.1) 581.5 (535.9, 630.8) 0.924
E1 232 67.0 (61.2, 73.2) 75.6 (70.2, 81.4) 0.044 67.5 (61.8, 73.6) 75.2 (70.0, 80.8) 0.065
E2 232 44.2 (40.1, 48.8) 51.3 (47.3, 55.7) 0.024 44.8 (40.6, 49.4) 50.7 (46.7, 55.0) 0.062
T/E2 ratio 232 4.6 (4.2, 5.0) 4.4 (4.0, 4.7) 0.500 4.5 (4.1, 4.9) 4.4 (4.1, 4.8) 0.831
A/E1 ratio 220 9.0 (8.0, 10.1) 7.7 (7.0, 8.5) 0.050 8.9 (7.9, 9.9) 7.8 (7.1, 8.5) 0.086
A, androstenedione; DHT, dihydrotestosterone; E1, estrone; E2, estradiol; SHBG, sex hormone-binding globulin; T, testosterone; 3α-diol-G,
3α-androstanediol glucuronide.
aAdjusted for age at surgery (year, continuous), race (European American, African American, other, unknown), study site (five sites, not listed here).
bAdditionally adjusted for BMI (<25.0, 25.0-29.9, ≥30.0 kg/m2), education (less than high school, high school/technical school, college or higher, unknown),
smoking status (never, former, current, unknown), and regular alcohol use (never, former, current, unknown).
cP-values were calculated for a global test of differences in geometric means.
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only) and did not find associations for serum testosterone, estradiol,
DHEA-S, or SHBG.22 Furthermore, another study in the US among
268 prostate cancer cases and controls found that men with vertex
balding had higher serum age- and race-adjusted free testosterone
levels than those who had little or no hair loss.47
This study supports associations of circulating sex hormones
with male pattern baldness in an older prostate cancer population.
However, comparisons between our results with previously pub-
lished studies requires caution. First, there is evidence that the
presence of prostate cancer may slightly suppress circulating
testosterone concentrations through the hypothalamic-pituitary
axis.48–51 Thus, associations observed in this case series may differ
from what may be expected in a healthy population. Second, our
analytical sample is older, compared to most prior studies, with a
mean age of 60 years. It is known that circulating testosterone
decreases,52–54 while male pattern baldness progresses with
advancing age.55 However, we would expect minimal confounding
by age in this study because distributions of age were not
statistically significantly different by balding status and we adjusted
for age in regression models.
Given the strong parallels in androgen dependency and in age-
related changes between scalp hair follicles and the prostate, we
speculated that male pattern baldness might serve as a proxy for
intrinsic enhanced androgenic action in androgen-responsive organs.
Such enhanced androgenic action may be partly explained by genetic
susceptibility, particularly within the AR signaling pathway. For
example, genetic variation in AR gene on the X-chromosome has
commonly been associated with male pattern baldness in European
descendants.56–58 Meanwhile, genes involved in androgen biosyn-
thesis and metabolism, as well as AR have been associated with
prostate cancer risk.59–61 Despite these shared etiological factors,
we did not find robust associations between intraprostatic sex
steroid hormones and male pattern baldness, although associations
were directionally consistent with our hypothesis. This implies that
sex steroid hormone-related factors (eg, AR), rather than the sex
steroids hormones themselves, play important roles in organ-specific
androgenic actions, and that other overlapping pathways may be
involved in associations between these two complex conditions.
Although the directional consistency could be explained by the field
effect of hormonal carcinogenesis on histologically normal tissue
and/or a product of reverse causation from the adjacent cancerous
foci—as supported by significantly elevated levels of testosterone,
DHT, and estradiol in normal tissue adjacent to Gleason ≥7 tumor
foci versus Gleason <7 foci (Supplemental Table S1)—we did not find
evidence that Gleason score modified the association between
intraprostatic sex hormones and balding status (Supplemental
Table S3).
Strengths of this study include central review by an experi-
enced genitourinary pathologist, nurse-assessed dermatological
characteristics, and simultaneous measurement of circulating and
intraprostatic sex steroid hormones. Limitations include the fact
that both circulating and intraprostatic sex hormones were only
measured once and, therefore, intra-individual temporal variations
could not be assessed. Meanwhile, male pattern baldness at older
age may reflect cumulative exposure to circulating sex steroid
hormones as opposed to the single time-point we have assessed in
serum and tissue at the age of prostate cancer diagnosis
(mean = 60, range = 37-86 years), and this mismatched time-
window of sex hormone exposure may have reduced statistical
power. Second, we combined hair-loss patterns because the
number of frontal balding only was relatively small. Although we
were unable to specify whether observed associations were
modified by hair-loss patterns, the misclassification of balding
status was minimized.
In conclusion, this study provides evidence that elevated
circulating testosterone, DHT, estradiol, and SHBG are associated
with balding status in prostate cancer cases. Male balding serves as a
proxy for circulating sex hormone concentrations and may explain
prior studies showing an association between male pattern baldness
and prostate cancer incidence and specific mortality. Testosterone is
the only elevated intraprostatic sex hormone in men with balding; lack
of an association between balding and other intraprostatic sex
hormones reaffirms differences in organ-specific sex steroid hormone
metabolism and cellular response.
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Supplemental Table 6. Adjusted geometric means of sex steroid hormones and SHBG by chest hair  
density and Gleason score (N=234)  
 
Supplemental Table 7. Adjusted geometric means of sex steroid hormones and SHBG by chest hair  
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Supplemental Fig 1. Modified Norwood-Hamilton Scale used to score hair loss patterns in NCI Prostate  
Tissue Study 
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2:83.7 
" " 
1.8I) 2 .21 ) 
" " " 
1.76) 1.89) 
w 
" p-trend' , , 0 .875 0.753 no n 
" 
0 .866 0 .988 
" <4.6 
" " 
1.00 (refe re nt) 1 .00 (refe re nt) 
" " " 
1 .00 (refe rent) 1 .00 (refe re nt ) 
1.24 {O.63, 1.35 {O.66, 0.86 (0.44 , 0.82 (0.41, 
4 .6 - 6 .3 
" " 
2.44) 2 .74) 
" " " 
1.66) 1.61) 
, 
 2.09 (1.00 . 2 .21 (0.99. 0.64 (0 .32. 0.69 (0 .33. 
2:6.4 
" " 
4 .39) 4 .96) 
" 
n 
" 
1.29) 1.46) 
w
" p-trend' , , 0.046 0.051 no n 
" 
0 .199 0 .335 
" <2.7 
" " 
1.00 (refe rent) 1 .00 (refe rent) 
" " " 
1 .00 (refe rent) 1 .00 (refe re nt) 
2 .58 (1. 31, 2 .7 0 (1. 33, 0.79 (0.42 . 0.82 (0.43. 
2 .7- 3.7 
" " 
5 .07) 5 .50) 
" " " 
1.48) 1.57) 
2 .74 (1. 29, 2 .94 (1. 3 3, 0.97 (0.48. 1.08 (0.52. 
2:3 .8 
" " 
5 .8 3 ) 6. 5}) 
" " 
B 1.98) 2 .25) 
w
" p ·trend' , , 0.0 10 0.009 no n 
" 
0 .976 0 .804 
TIE2 Ratio 
<124 .9 
" '" 
1.00 (refe rent) 1 .00 (refe rent) 
" " " 
1 .00 (refe rent) 1 .00 (refe re nt) 
124.9- 0.87 (0.46. 0.96 (0 .48. 1.23 (0 .67. 1.14 (0.60. 
180.8 
" " 
1.66) 1.90) 
" " " 
2 .28) 2 .19) 
0.98 (0.50, 1.13 (0.5 5, 2 .18 (1 . 14, 1.94 (0.96. 
2: 180.9 
" " 
1.91) 2 .36) 
" " " 
4. 1 8) 3.94) 
w
" p-t rend' , , 0.982 0.707 no n 
" 
0 .0 1 7 0 ,056 
NEI Ratio 
<10,3 
" " 
1.00 (refe rent) 1 .00 (refe rent) 
" 
n 
" 
1 ,00 (refe rent) 1 ,00 (refe re nt) 
0.65 (0.33, 0.66 (0.33, 1.63 (0 .85, 1.71 (0.88, 
10.3- 15 ,3 
" " 
1.26) 1.34) 
'" " " 
3 .13) 3.35) 
0.88 (0.44, 0.99 (0 .47, 1.51 (0 .79, 1.53 (0.77, 
2: 15.4 
" " 
1.76) 2 .08) 
" 
n 
" 
2 .89) 3.03) 
W 
" p-t rend' , , 0.977 0.720 no n 
" 
0 ,328 0 ,391 
'"eG (nmol/U 
<28,0 
" " 
1.00 (refe re nt) 1 .00 (refe rent) 
" " " 
1 ,00 (refe rent) 1 ,00 (refe re nt) 
1.26 (0.67, 1.22 (0.6 2, 1.28 (0 .69 . 1.14 (0.61, 
28.0- 39.4 
" " 
2 .39) 2.40) 
" " " 
2 .37) 2 .16) 
3 .49 (1.69, 3 .81 (1. 75, 2 .23 (1.14, 1.80 (0 .90, 
2:39,5 
" " 
7 .2 4 ) 8 .3}) 
" " 
B 4.35 ) 3 .59) 
w
" p-t rend' , , 0.0 0 1 <0.001 no n 
" 
0 .0 16 0 ,086 
Free T 
<9.9 
" " 
1.00 (refe re nt) 1 .00 (refe rent) 
" " " 
1 ,00 (refe rent) 1 ,00 (refe re nt) 
1.08 (0.5 7, 1.25 (0.64, 1.12 (0 .61. 1.25 (0.66, 
9 ,9 - 13,1 
'" " 
2 .04 ) 2.45) 
" " " 
2 .06 ) 2 .34) 
2 .08 {1.06 , 2 .53 (1. 23, 1.12 (0 .59. 1.05 (0 .54 , 
2: 13,2 
" " 
4.1 }) 5 .23) 
" " 
B 2 .11) 2 .06) 
, 
 w 
" p-trend' , , 0 .0 33 0.0 12 no n 
" 
0 .737 0 .876 
Free E2 
<0.074 
" " 
1.00 (referent) 1 .00 (referent) 
" 
n 
" 
} ,OO (refe rent ) } ,OO (referent) 
0 ,074- 1.94 (l .00, l.87 (0.93. 0.50 (0 .26. 0.56 (0 .29. 
0 .103 
" " 
3 .78) 3 .77) 
" " " 
0 .95) 1.08) 
1.66 (0 .81, 1.57 (0.73, 0 .60 (0 .30. 0 .69 (0 .33. 
",0 .104 
" " 
3.41) 3 .37) 
" " " 
1.20) 1.43) 
w 
" p-trend' , , 0 .239 0 .352 no n 
" 
0 .242 0.470 
Adjacent normal prostate tissue (pgJg WI 
T 
<181.8 
" " 
1.00 (referent) 1 .00 (referent) 
" 
n n } ,OO (refe rent ) } ,OO (refe rent ) 
181.8- 0 .74 (0 .38, 0 .76 (0.39. 1.25 (0 .67. 1.36 (0 .72. 
255.4 
" " 
1.43) 1.51) 
" " 
n 2 .32) 2 .56) 
1.19 (0 .60, l.25 (0 .61, 1.16 (0 .61 . 1.17 (0 .60. 
2:255 .5 
" " 
2 .39) 2 .57) 
" 
n 
" 
2 .22) 2 .27 ) 
W 
" p-trend' , , 0 .531 0.466 
'" 
n 
" 
0 .690 0 .691 
O>IT 
<6065.5 
" " 
1.00 (referent) 1 .00 (referent) 
" " " 
} ,OO (refe rent ) } ,OO (referent ) 
6065.5 - 1.13 (0 .5 9, l.10 (0 .5 6, 1.87 (0 .99. 1.88 (0 .98. 
7492.6 
" " 
2 .17) 2 .16) 
" " " 
3 .50) 3 .58) 
1.24 (0 .65. 1.29 (0.65. 1.60 (0 .86. 1.75 (0 .91. 
2:7492.7 
" " 
2 .38) 2 .57) 
" " 
n 3 .00 ) 3 .39) 
" " p ·t rend' , , 0 .514 0.473 no n 
" 
0 .129 0 .087 
3a-d iol-G 
<2254.2 
" " 
1.00 (refe re nt) 1 .00 (refe re nt) 
" 
n 
" 
1 .00 ( refe rent ) 1 .00 (refe re nt ) 
2254.2- 1.12 (0 .5 7. 1.14 (0 .5 7. 0.73 (0 .39. 0.80 (0.42. 
3198.8 
" '" 
2 .17) 2 .29) 
" " " 
1.37) 1.55) 
1.18 (0 .60. 1.35 (0 .67. 0.89 (0.47. 1.0 5 (0 .54. 
2:3198.9 
" '" 
2 .29) 2 .74) 
" " " 
1.67) 2 .03) 
" " p ·t rend' , 0 0 .639 0.401 
'" " " 
0 .790 0 .798 
A 
<473.4 
" " 
1.00 (refe re nt) 1 .00 (refe re nt) 
" 
n 
" 
1 .00 ( refe rent ) 1 .00 (refe rent) 
473.4- 0 .79 (0.40. 0 .90 (0.44. 1.06 (0 .55. 1.10 (O.56. 
726.3 
" " 
1.57) 1.84) % 
" " 
2 .04 ) 2 .14) 
0 .67 (0 .33. 0 .7 0 (0.34. 0.99 (0 .51. 1.10 (O.55. 
2:726.4 
" " 
1.36) 1.45) 
" " " 
1.92) 2 .18) 
B 
p ·t rend' 
" 
, 0.280 0 .326 
'" 
n 
'" 
0 .950 0 .808 
" 
" 
 <59,1 
" '" 
1.00 (refe rent) 1 .00 (refe rent) 
" 
n 
" 
1 ,00 (refe rent) 1 ,00 (refe re nt ) 
1.69 (0.36 , 1.75 (0.37, 0.73 (0.41. 0.37 (0.45. 
59.1-36.1 
" '" 
3 .30) 3 .53) 
" " 
n 1.43) 1.67) 
2.13 (1.0 4, 2 .13 (0.99. 0.57 (0 .29. 0.72 (0.35. 
2:36,2 n 
'" 
4. 37) 4 .59) 
" " " 
1.14 ) 1.47) 
B 
p ·trend' 
" • 
0 .043 0.053 
'" 
B 
" 
0 ,111 0 ,365 
" <40,7 
'" " 
1.00 (refe rent) 1 .00 (refe rent) 
" 
n 
" 
1 ,00 (refe rent) 1 ,00 (refe re nt ) 
1.34 (0.69. 1.31 (0.65, 0.71 (0 .37. 0.79 (O .41. 
40.7 - 57.5 
" " 
2.63) 2 .64) 
" " '" 
1.35) 1.52) 
1.95 (0.98, 1.94 (0.93. 0.65 (0 .34 . 0.77 (0 .39. 
2:57 ,6 
" " 
3 .89) 4 .01) 
" " " 
1.27) 1.54) 
B 
p ·trend' 
" • 
0.058 0.075 
'" 
B 
" 
0 ,228 0 ,481 
TlE2 Ratio 
<3.3 
" " 
1.00 (refe rent) 1 .00 (refe rent) 
" " " 
1 ,00 (refe rent) 1 ,00 (refe re nt ) 
0.91 (0.47, 0.88 (0.43. 1.10 (0 .59. 1.01 (0.52. 
3 ,8 -5.1 
" " 
1.73) 1.78) 
" " 
n 2 .08 ) 1.95) 
1.02 (0.5 2. 1.19 (0.60, 1.66 (0 .88. 1.57 (0 .82. 
2:5 .2 
" " 
1.97) 2 .37) 
" " " 
3 .15) 3.01) 
B 
p ·trend' 
" • 
0.917 0.54 3 
'" 
B 
" 
0 ,105 0 ,145 
NEIRatio 
<6.1 
" " 
1.00 (refe rent) 1 .00 (refe rent) 
" " 
W 1 ,00 (refe rent) 1 ,00 (refe re nt ) 
0.67 (0.32. 0.68 (0.32, 1.00 (0 .52. 1.01 (0.51. 
6 ,1- 10,3 
" " 
1.37) 1.44) 
" " " 
1.94 ) 1.99) 
0 .42 (0.20, 0 .45 (0.21, 1.55 (0 .76. 1.45 (0.70. 
2: 10.4 
" " 
0.88) 0.97) 
" " " 
3 .13) 3 .00) 
B 
p ·trend' 
'" 
0 0 .022 0 .042 
" " " 
0 ,191 0 ,232 
Abbreviations: T, testO".iteronf: DHT, dihydrotestosterone; 3a.<Jiol-G, 3a-aodrostaItediol glucuronide; A, aodro-.itenedione; El, estrone; E2, estradiol; SHBG, sex 
hOImoDe-hinding globulin . 
• Adjusted for age at surgery (;'ear, continuous), race (European American, African American, other, unloown), study site (5 sites, Dot listed !tere) 
t Additionally adjusted for BMI «25,0. 25.0--29.9, ~30 , 0 kglm'J, education (less than high school, high ,chool/technical school, college or higher, unknown), 
SIIIoking status (never, forme!, C\lITI'IIt, unknown) and regular alcohol use (never, former, C\lITI'IIt, unknown). 
'p-trend was calrnlaled by assi~g median values for each tertile of sex hormones and SHBG as a CO!Ilin\1OllS vmable in logisti<: "'W"'sion models. 
 SUI!I!L~m~ntal 'IlIbL~ 6. Ad jusu.d'll""metri( lIN'ans 01 """ st~l'Oid hormon~ and SHBG by ch~t hair density and GI~ilSOn ",,0..., IN-234) 
GleitSOn "'0 .... <7 (N 130) Gleason "'01"1':>7 (N 104) 
S& honnoo ... N Noo",,",," Mod ... ~~ ,~ N NoMlS~ J\.lod..-at.m.ns.. , , 
(n=52) (n- 73} ,al",,' (n=4B} (n=56} valu~' val"': 
, Mrum (ncIdI} • .. 
, 
"" 
469.2 (417.0, 527.9) 439.9 (397.2, 487.1) 0.449 
'"' 
472.7 (418.5, 533.9) M7.3 {.tOO.3, 499.8} 
"'" 
0.553 
mIT 
"" 
52.1 (46.9, 57.9) 50.7 (46.2, 55.5) 0106 
'"' 
5O.5 {4.t7,57.1) 5O.0 {M .7,55.9) 
""" 
OA93 
Ja-diol-G 
"" 
510.2 (M2.9, 587.9) 544.0 (48L3, 614.9) 0.532 
'"' 
46L6{392 .0, '>43.7) 498.0 (429.0, 578.1) 0.535 OA91 
A 
"" 
74.1 (65.5, 83.8) 70.2 (53.2, 78.1) 0.548 
'"' 
67.5 (59.3, 76.7) 66.1 (":.8.8, 74.4) 
"'" 
0.725 
n 
"" 
5.5 {4.9,6.1) 5.5{5.0, 6.0) 
"."" '"' 
4.7 (4.3, 5.2) 5A (5.0, 5.9) 0.049 OA51 
" "" 
3.2 (H, 3.6) 3.1 (2.8, 3.4) 
""" '"' 
2.9 (2.6, 33) 3.1 (2.8, 3.4) 0.521 0.185 
TlE2 Ratio 
"" 
147.1 (13L8, 164.1) 142.1 (129.2, 156.2) 
"'" '"' 
H;1l7 (140.9, 1833) IM .I (ln8, 162.4) 
""" 
0.529 
AIEl Ratio 
"" 
l3.5 {IL9, 15.2) l2.8 {IL 5, 14.2) 0.555 
'"' 
14.3 (Ib, 16A) ILl (10.8, 13.8) 0.116 
"'" SHBG, omollL 
"" 
32.8 (29.5, 36.4) 32.3 (29.5, 35.4) 0.852 
'"' 
MA (30.5, 38.7) 3L 7{28.4, 35.4) 0381 0.861 
""'" "" 
11S (l OA, IV) 10.8 (9.9, 11.8) 0379 
'"' 
IU {10.2,l2.6) ILl (1O.0, ILl) 0.759 OA16 
""n 
"" 
0.09 (0.118, 0.10) 0.09 (0.08, 0(9) 0148 
'"' 
008 (0.D7, 0.(9) 0.09 (0.08,0.10) 0347 0.153 
A<¥<mt normaIl!rosrn~ tissuo !P&IIl W} 
, 
"" 
210S (189.0, 2M.6) "}f)9 7 (19LO, 230.2) 0.958 
'" 
243.1 (207.4, 284.8) 219.6 {190.6, 253.0} 
"'" 
0.937 
mIT 
"" 
66673 {6148.5, 7229.9) 6095.1 (5682S, 6537.6) 0.128 
'"' 
6993S (6419.9, 7618.4) 6781 .6 (6272A, 7332.0) 
"'"" 
0.074 
Ja-diol-G 
'" 
264.tl (2362 .7, 2959.0) 253L8 (2296.8, 2791 .0) 0.594 
'" 
2906.3 (2 S4 L3, 3323.8) 27M.7 (2417.8, 3093.0) 
"'" 
0.882 
A m 555.1 (489.4, 629.6) 583.6 (52L3, 653.4) 0.588 ,; 63L9 (527.9, 756.5) 574.5 (490.1, 673.4) OA73 "300 
n m 73.9 (65.2, 83.7) 69.5 (62.3, nS) 0.495 
" 
65A (57.0, 75.0) 75.6 (66.8, 85.5) 0.155 0.049 
" 
m 46.9 (41.2, 53.5) 45.0 (40.I, 50.4) 0.651 
" 
49.0{4L7, 57.6) 5L8 {M .8,59.9) ".00 0.171 
TIE.2 Ratio m 4.4{3.8,5.0) 4.5{4.0, 5.0) 0.760 
" 
4.8{.tl, 5.7) 4.1 (3.6,4.8) 0.192 0.140 
AIEl Ratio 
'" 
7.5 (6.4, 8.8) 8.5Q.4,9.8) 0.272 
'" 
9.8 (82, 11.7) 7.5 (63, 8.8) ,.'" 11.1112 
Abbreviations: T, testO".iterone; DHT, dihydrotestosterone; la-<liol-G, 3a-ao<lrostanl'lliol glucuronide; A, aodro-;tenedione; El, estrone; E2, estradiol; SHBG, se" 
bOlmoDe-binding globulin . 
• Adjusted for age at surgery (year, continuous), race (European American, African American, other, unknown) , study site (5 sites, nOl listed here), BMI (<25.0, 
25.0---29.9, :>30,0 kgfm2), education (less than bigil school, bigil scboolltechnical school, college or higber, unknown), smoking status (never, fonner, current, 
unknown) and regular alcohol use (never, fonner, C\lITI'Dt, unknown). 
' P -values were calculated lor a global test 01 differences in geometric means. 
'P-values were calculated lor the multiplicative interaction between balding stams and Gleason score , 
 hmmone-hinding glohulin . 
• Adjusted for age at surgery (year, continuO\lS), .rudy <ite (5 sites, not listed here), BM! (<25.0, 15.()"'19.9, ~30.0 kgIm'), education (le<;s than high "'hool, high 
schoolltedmical school, college or higher, unknown), smoking sta:tIs (never, lormer, CllITI'Di, unknown) and regular alcohol use (never, lormer, CllITI'Di, unknown). 
'P -values were calculated for a glohal test 01 dillerenees in geome~ic mean,. 
'P-values were calculated for the multiplicative interaction betw""" halding stams and race (European American ,.... African American). 
 Supplemental Fig 1. Modified Norwood-Hamilton Seal. usN! to sco~ hair loss patlerns in NCI 
Prostat~ 'Jis5U~ Study 
No baldn.,." 
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